Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio, today announced ...

Evolus Inc . (NASDAQ:EOLS), a company specializing in aesthetic products with a market capitalization of $933 million, has recently made significant strides in expanding its product portfolio and ...

Evolus (EOLS) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate ...

HC Wainwright reissued their buy rating on shares of Evolus (NASDAQ:EOLS – Free Report) in a research report report published on Friday,Benzinga reports. HC Wainwright currently has a $27.00 price ...

Evolus said on Thursday the U.S. Food and Drug Administration has approved its two new anti-wrinkle injectable gels, expanding the company's product portfolio beyond its cosmetic injection Jeuveau.

EST Evolus (EOLS) trading halted, news pendingMaximize Your Portfolio with Data Driven Insights:Leverage the power of TipRanks' Smart ...

Evolus (EOLS) announced that the Food and Drug Administration has approved Evolysse Form and Evolysse Smooth injectable hyaluronic acid gels, ...

Evolus said the Food and Drug Administration approved its injectable hyaluronic acid gels, known as Evolysse Form and Evolysse Smooth, in line with management expectations.

Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio, today announced that the U.S. Food and Drug Administration (FDA) has approved Evolysse™ ...